Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow.
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).
Up to one-third of patients undergoing surgery in Ontario have a treatable form of anemia but are not optimally treated for it.
NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease.
Medgenics, Inc., the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics' EPODURE Biopump technology for delivery of erythropoietin (EPO).
As a growing number of biologic drugs are treatments of choice for an expanding list of autoimmune disorders, inflammatory diseases, and certain cancers, bioassays play a critical role in establishing the functional integrity and potency of these products.
Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.
Duke Medicine researchers studying the interaction of blood stem cells and the niche where they reside have identified a protein that may be a long-sought growth factor for blood stem cells.
PROLOR Biotech, Inc. today announced positive results from a preclinical toxicology study designed to assess the safety and tolerability of PROLOR's proprietary long-acting reversible-pegylation technology.
Multiple doses of erythropoietin in combination with hypothermia could be neuroprotective in neonates with hypoxic‑ischemic encephalopathy, say researchers.
Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.
Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.
A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment.
Two cellular proteins team up to provide a steady supply of red blood cells (RBCs), according to a study by Lizhao Wu, PhD, of the University of Medicine and Dentistry of New Jersey-New Jersey Medical School, and colleagues.
PROLOR Biotech, Inc., announced that the company will present data today on its long-acting clotting factors for the treatment of hemophilia at the World Federation of Hemophilia (WFH) World Congress.
Jehovah’s Witness patients who refuse blood transfusions during cardiac surgery are not at risk for surgical complications or long-term mortality compared with non-Witnesses who receive transfusions, report US researchers.
Jehovah’s Witnesses do not have a significantly increased risk for complications or long-term mortality after cardiac surgery, researchers say.
Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that its INFRADURE Biopump has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for the treatment of hepatitis D.
As science rushes to develop safe weight loss drugs, a new research report approaches this problem from an entirely new angle: What if there were a pill that would make you want to exercise harder? It may sound strange, but a new research report appearing online in The FASEB Journal suggests that it might be possible.
Medgenics, Inc., developer of the novel Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the U.S. Food and Drug Administration to proceed with a Phase IIb clinical trial of EPODURE for the treatment of anemia in patients undergoing renal dialysis.